A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with

Project: Other project

Project Details

StatusActive
Effective start/end date2/15/2112/31/21

Funding

  • Novartis Pharmaceuticals Corporation: $8,123.08